- Stocks
- Pharma & Healthcare
- Rainbow Childrens Medicare
Rainbow Childrens Medicare share price
NSE: RAINBOWPharma & HealthcareMedical Care Facilities
Rainbow Childrens Medicare at a glance
Rainbow Childrens Medicare (NSE: RAINBOW) closed at ₹1,205.70 on 22 Oct 2026, down 0.27% on the day. With a market capitalisation of ₹12,245 Cr, it ranks 502nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 43.9× trailing earnings, against a return on equity of 16.9% in FY26. Over the past year the share price has fallen 9.4%. Its 52-week range is ₹1,084.00 (23 Mar 2026) to ₹1,610.00 (5 Aug 2026); the last close is 25.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹470 Cr (+33.2% year on year) and net profit ₹63 Cr (+16.2%), on a consolidated basis. Promoters held 49.84% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹12,245 CrRank 502 on NSE
- P/E (trailing)
- 43.9×
- Price to book
- 7.17×FY26
- EPS (TTM)
- ₹28.11to Q1 FY27
- ROE
- 16.9%FY26
- ROCE
- 16.9%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 16.5%FY26
- Book value / share
- ₹162.28FY26
- Dividend payout
- 10.9%FY26
- 52-week high
- ₹1,610.005 Aug 2026
- 52-week low
- ₹1,084.0023 Mar 2026
- 1-year return
- −9.4%
- RSI (14-day)
- 31.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.27% | −4.1% | −16.4% | −18.7% | −9.4% |
Rainbow Childrens Medicare quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹417 Cr | ₹398 Cr | ₹370 Cr | ₹353 Cr | ₹445 Cr | ₹445 Cr | ₹460 Cr | ₹470 Cr |
| Revenue YoY | +25.5% | +18.5% | +8.5% | +6.9% | +6.5% | +11.9% | +24.3% | +33.2% |
| Net profit | ₹79 Cr | ₹69 Cr | ₹57 Cr | ₹54 Cr | ₹76 Cr | ₹74 Cr | ₹78 Cr | ₹63 Cr |
| Net profit YoY | +25.1% | +10.2% | +10.7% | +35.4% | −4.3% | +7.2% | +38.3% | +16.2% |
| Net margin | 18.9% | 17.3% | 15.3% | 15.2% | 17.0% | 16.6% | 17.0% | 13.3% |
| EPS | ₹7.77 | ₹6.76 | ₹5.55 | ₹5.27 | ₹7.41 | ₹7.14 | ₹7.59 | ₹5.97 |
Rainbow Childrens Medicare financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹650 Cr | ₹974 Cr | ₹1,174 Cr | ₹1,297 Cr | ₹1,516 Cr | — |
| Operating profit | ₹56 Cr | ₹187 Cr | ₹282 Cr | ₹295 Cr | ₹330 Cr | — |
| Net profit | ₹40 Cr | ₹139 Cr | ₹212 Cr | ₹218 Cr | ₹244 Cr | — |
| EPS (₹) | ₹4.00 | ₹15.00 | ₹21.00 | ₹21.00 | ₹24.00 | — |
| Cash from operations | ₹143 Cr | ₹224 Cr | ₹327 Cr | ₹321 Cr | ₹396 Cr | — |
| Total debt | ₹41 Cr | ₹27 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹446 Cr | ₹603 Cr | ₹1,060 Cr | ₹1,259 Cr | ₹1,468 Cr | ₹1,648 Cr |
Rainbow Childrens Medicare shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 49.85% | 49.85% | 49.85% | 49.84% | 49.84% | 49.84% |
| Foreign institutions | 23.69% | 23.59% | 21.85% | 19.23% | 17.24% | 16.03% |
| Domestic institutions | 15.31% | 15.44% | 17.46% | 19.49% | 21.13% | 22.56% |
| Non-institutions | 11.14% | 11.11% | 10.84% | 11.40% | 11.67% | 11.39% |
Rainbow Childrens Medicare vs peers
The listed Pharma & Healthcare companies nearest to Rainbow Childrens Medicare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| CONCORDBIOConcord Biotech | ₹1,298.00 | +1.80% | −14.6% | ₹13,579 Cr | 52.4 | — |
| MARKSANSMarksans Pharma | ₹295.80 | −0.89% | +62.6% | ₹13,405 Cr | 32.1 | — |
| CORONACORONA Remedies | ₹2,024.70 | −0.26% | — | ₹12,383 Cr | 66.8 | — |
| RAINBOWRainbow Childrens Medicare | ₹1,205.70 | −0.27% | −9.4% | ₹12,245 Cr | 43.9 | — |
| SUDEEPPHRMSudeep Pharma | ₹984.90 | +1.02% | — | ₹11,124 Cr | 66.2 | — |
| METROPOLISMetropolis Healthcare | ₹532.25 | −0.03% | +9.2% | ₹11,035 Cr | 57.9 | — |
| AKUMSAkums Drugs and Pharmaceuticals | ₹690.85 | −0.17% | +50.2% | ₹10,874 Cr | 41.5 | — |
Ask anything about Rainbow Childrens Medicare
Pivot answers on the live chart with evidence you can check, and tests strategies against RAINBOW's own history. Try: “Why has RAINBOW moved over the last three months?” · “Backtest a 50-day moving-average crossover on RAINBOW over five years” · “Compare RAINBOW with CONCORDBIO on margins and valuation”
Frequently asked questions about Rainbow Childrens Medicare
What is the share price of Rainbow Childrens Medicare today?
Rainbow Childrens Medicare (NSE: RAINBOW) last closed at ₹1,205.70 on 22 Oct 2026. Its 52-week high is ₹1,610.00 and its 52-week low is ₹1,084.00.
What is the market cap of Rainbow Childrens Medicare?
Rainbow Childrens Medicare's market capitalisation is ₹12,245 Cr (₹12,245 Cr) at the 22 Oct 2026 close, ranking 502nd among the NSE companies Pivot tracks.
What is the P/E ratio of Rainbow Childrens Medicare?
Rainbow Childrens Medicare trades at a trailing P/E of 43.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 57.9.
What is the ROE and ROCE of Rainbow Childrens Medicare?
Return on equity was 16.9% in FY26 and return on capital employed was 16.9% in FY26 (consolidated figures).
Is Rainbow Childrens Medicare a debt-free company?
Rainbow Childrens Medicare is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Rainbow Childrens Medicare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Rainbow Childrens Medicare reported revenue of ₹470 Cr, +33.2% year on year, and net profit of ₹63 Cr, +16.2% year on year.
How has Rainbow Childrens Medicare stock performed over the last year?
Rainbow Childrens Medicare's share price has fallen 9.4% over the past year, −18.7% over three months and −16.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Rainbow Childrens Medicare?
As of 30 Jun 2026: promoters 49.84%, foreign institutions 16.03%, domestic institutions 22.56%, non-institutions 11.39%.
Who are Rainbow Childrens Medicare's competitors?
The listed Pharma & Healthcare companies closest to Rainbow Childrens Medicare by market cap are Concord Biotech, Marksans Pharma, CORONA Remedies, Sudeep Pharma, Metropolis Healthcare and Akums Drugs and Pharmaceuticals.
Is Rainbow Childrens Medicare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Rainbow Childrens Medicare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on RAINBOW against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with R · all NSE stocks · this page as text